Enanta Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $360.3M
- Price
- $12.37
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.64%
- Volume
- 191.7K
About
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Quick stats
Shares outstanding29.1M
Computed float27.4M
Float / shares94.2%
Cash runway (months)55.9
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001177648
Websitehttps://www.enanta.com
AI Summary
AI-generated1/12
minorneutralother
Enanta Pharmaceuticals to Participate in September Investor Conferences
Enanta Pharmaceuticals announced that members of its management team will participate in two investor conferences during September.
The company is scheduled to attend the Baird 2026 Global Healthcare Conference on September 15 and the H.C. Wainwright 28th Annual Global Investment Conference on September 16.
Live webcasts and subsequent replays of the presentations will be made available on the Investors section of the company’s website.